Navigation Links
Optimer Pharmaceuticals Phase 3 Clinical Trials show Fidaxomicin is Superior to Vancomycin in Treatment of Recurrent Clostridium difficile Infection (CDI); Data Presented at ICAAC
Date:9/14/2010

onCDI has become a significant medical problem in hospitals, long-term care facilities, and in the community.  It is a serious illness caused by infection of the inner lining of the colon by C. difficile bacteria, which produces toxins that cause inflammation of the colon, severe diarrhea and, in the most serious cases, death.  Patients typically develop CDI from the use of broad-spectrum antibiotics that disrupt normal gastrointestinal (gut) flora, and thus allowing C. difficile bacteria to flourish.

Current therapeutic options for CDI include the off-label use of metronidazole and oral vancomycin, the only FDA-approved treatment.  However, approximately 20% to 30% of CDI patients who initially respond to these treatments experience a clinical recurrence following cessation of antibiotic administration.

Primary risk factors for CDI include broad-spectrum antibiotic use (such as cephalosporins and fluoroquinolones), advanced age (over 65) and exposure to emerging hyper-virulent strains (BI/NAP1/027, 078, 001) of C. difficile. Increasing incidence, higher treatment failures and recurrence with current therapies have resulted in greater awareness and concern of CDI among medical professionals and public health officials.

About FidaxomicinFidaxomicin is the first in a new class of antibiotics called macrocycles, which inhibit the bacterial enzyme RNA polymerase, resulting in the death of C. difficile. The narrow-spectrum profile of fidaxomicin may eradicate C. difficile selectively with minimal disruption to the normal intestinal flora, while the alternative antibiotics to treat CDI, metronidazole and vancomycin, disrupt the flora. Fidaxomicin may facilitate the return of normal physiological conditions in the colon which may be responsible for reducing CDI recurrence.

About Optimer PharmaceuticalsOptimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discoverin
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Optimer Pharmaceuticals Reports Third Quarter 2009 Financial Results
2. Optimer Pharmaceuticals to Present at September 2009 Investor Conferences
3. Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting
4. Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
5. Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference
6. Optimer Pharmaceuticals to Present at June 2009 Investor Conferences
7. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
8. Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
9. Edimer Pharmaceuticals and CMC Biologics Announce Agreement to Manufacture EDI200 Recombinant Protein
10. Transdel Pharmaceuticals to Present at Rodman & Renshaw 12th Annual Healthcare Conference
11. Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare and Baird Global Healthcare Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... , May 26, 2015  Alere Inc. (NYSE: ... of its failure to timely file its Quarterly Report on ... (the "Form 10-Q"), it has received a notice from the ... not in compliance with the NYSE,s continued listing requirements under ... NYSE Listed Company Manual. The reason for ...
(Date:5/26/2015)... NJ (PRWEB) May 26, 2015 OHAUS ... balances and scales, is set to release a new ... of quality-driven laboratory instruments. For over a century, the ... in weighing technology throughout the world. Now in ... has gone Beyond Weighing to include water quality measurement. ...
(Date:5/26/2015)... 26, 2015 Pharmaco-Kinesis Corporation (PKC) announced today ... at Shutters on the Beach in Santa ... of the Company,s innovative Metronomic Biofeedback Pump (MBP), a ... chemotherapy over time to a target site of the ... biofeedback system in real-time.  ...
(Date:5/26/2015)... , May 26, 2015 Mr. Kevin Xu ... thanks President Barack Obama and President Bill ... time of loss of Dr. Rongxiang Xu , Kevin,s ... a leader ahead of his time, Dr. Xu,s commitment to ... leave a legacy that will not be forgotten. As a ...
Breaking Biology Technology:OHAUS Corporation to Release New Water Analysis Meters in 2015 2OHAUS Corporation to Release New Water Analysis Meters in 2015 3Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 2Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 3Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 4Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 5Dr. Rongxiang Xu, Beyond A Legend 2
... Guide New Service Offering, PHILADELPHIA, Feb. 7 ... Alzheimer,s risk assessment service,with the appointment of a medical ... leading laboratory testing companies in the world., "Our ... accurate,information about their genetic risk, help them understand and ...
... Calif., Feb. 7 Documents,detailing the California stem ... relations firm reveal an agency,leadership worried about the ... secret by channeling it through an outside law ... said today., The stem cell institute, a ...
... In a speech to be delivered Tuesday,February 12th, ... Conference,at the New York Grand Hyatt Hotel, U.S. ... Thompson, will propose that,prevention is the solution for ... together experts from throughout the health care industry,to ...
Cached Biology Technology:Smart Genetics Announces Plans to Launch a New Alzheimer's Risk Assessment Service 2Smart Genetics Announces Plans to Launch a New Alzheimer's Risk Assessment Service 3'Crisis Management' PR Firm's Advice to Stem Cell Agency Laundered Through Law Firm to Avoid Scrutiny 2'Crisis Management' PR Firm's Advice to Stem Cell Agency Laundered Through Law Firm to Avoid Scrutiny 3U.S. Preventive Medicine National Policy Advisor Gov. Tommy Thompson to Propose Prevention is the Solution at UBS Global Health Services Conference 2
(Date:5/18/2015)... GOTHENBURG, Sweden , May 18, 2015 ... touch fingerprint sensors FPC1020, FPC1025, FPC1145, FPC1155 and FPC1035 from ... place from June until and including Q3 2015 and the ... Asia . Communicated order values for 2015 hereby amount ... revenues for Q1 2015 of 140 MSEK and a number ...
(Date:5/11/2015)... , May 11, 2015 Curemark LLC, ... the start of a new Phase III double blind, ... its novel formulation, CM-AT, on all children ages 3-8 ... its FDA Phase III double blinded clinical trial for ... low levels of the digestive enzyme chymotrypsin. This new ...
(Date:5/5/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), ... market, reminds investors and media that  Mr. David Tunnell ... SECURE CONNEXIONS AMERICA 2015, held in Washington DC ... conference is organized into a series of nine session tracks. ... Fraud: Where is the Trust in Cyberspace? and will ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3
... new study in the July 18 issue of The ... more harmful than their unpigmented relatives. A group of ... have discovered that the molecules that give certain bugs ... cells called neutrophils. , Scientists and clinicians have known ...
... Microbiologists seeking ways to eliminate pollution from waterways with ... in freshwater ponds can generate electricity. They present their ... American Society for Microbiology. , "The bacteria are capable ... used to operate small electronic devices. As long as ...
... of that group of diseases, affects 500 000 people in ... Leishmania infantum, transmitted by sand fly bites. There is no ... if no treatment is given. In the most heavily affected ... acts as parasite reservoir for humans. Development of a vaccine ...
Cached Biology News:Pollution-eating bacteria produce electricity 2Visceral Leishmaniasis: Successful Vaccine Trial In Dogs 2Visceral Leishmaniasis: Successful Vaccine Trial In Dogs 3Visceral Leishmaniasis: Successful Vaccine Trial In Dogs 4
Phospho-4E-BP1 (Thr37/46) (236B4) Rabbit mAb Shipping Temperature: Cold Storage Temperature: -20C...
RNA polymerase sigma 70 Immunogen: Recombinant, full length protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Rat monoclonal to UGGT ( Abpromise for all tested applications)....
...
Biology Products: